JMP Securities Maintains Outperform on Integra Lifesciences, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly maintains an Outperform rating on Integra Lifesciences (NASDAQ:IART) but lowers the price target from $65 to $60.
July 28, 2023 | 10:54 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Integra Lifesciences' price target has been lowered from $65 to $60 by JMP Securities, though the Outperform rating is maintained.
The news directly pertains to Integra Lifesciences. While the Outperform rating is maintained, the lowering of the price target could indicate a potential slowdown in growth or a reassessment of the company's value. This could have a neutral impact on the stock price in the short term as the market absorbs this information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100